Latest Breaking News On - Armentum partners - Page 3 : vimarsana.com
Search jobs 08-Apr-2021 Celcuity Reports Preliminary Data from Phase 1b Trial of Gedatolisib plus Ibrance® and Endocrine Therapy for Patients with ER+/HER2- Metastatic Breast Cancer and Provides Corporate Update
Preliminary Phase 1b Data
- Gedatolisib showed a potentially differentiated safety and tolerability profile -
Corporate Update
- Proceeds from first $15 million tranche increase cash-on-hand to $44 million -
- Drug development capabilities and team broadened and expanded -
- Conference call and webcast scheduled for today, April 8 at 5 p.m. Eastern Time -
MINNEAPOLIS (BUSINESS WIRE) Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today reported preliminary data for the 103 patients enrolled in the expansion portion of an ongoing Phase 1b clinical trial evaluating gedatolisib, a first-in-class PI3
Sheri-smith
Bernhard-lampert
Celsignia-cdx
Arthur-decillis
Bristol-myers-squibb
Vicky-hahne
Marie-degayner-kuker
Robert-uhl
Johnr-macdonald
Brian-sullivan
Regulatory-affairs-professionals-society
Exchange-commission-on